Get started
Author

Yang Liu

Diffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment
2019 · Yang Liu, Stefan Klaus Barta · American Journal of Hematology · 489
PDF
Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy
2020 · Nicole A. Carreau, Orrin Pail, et al. · The Oncologist · 50
PDF
Outcomes in patients with aggressive B‐cell non‐Hodgkin lymphoma after intensive frontline treatment failure
2019 · Emily C. Ayers, Shaoying Li, et al. · Cancer · 36
PDF
Clinical Study of Autologous Cytokine-Induced Killer Cells for the Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma
2011 · Xue-chun Lu, Bo Yang, et al. · Cell Biochemistry and Biophysics · 36
Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma
2021 · Peifeng Li, Jia Chai, et al. · Frontiers in Oncology · 26
PDF
EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features
2017 · Yang Liu, Kangjie Yu, et al. · Human Pathology · 24
Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma
2020 · Reid W. Merryman, Nicole A. Carreau, et al. · The Oncologist · 16
PDF
Clinical Utilization Pattern of Liquid Biopsies (LB) to Detect Actionable Driver Mutations, Guide Treatment Decisions and Monitor Disease Burden During Treatment of 33 Metastatic Colorectal Cancer (mCRC) Patients (pts) at a Fox Chase Cancer Center GI Oncology Subspecialty Clinic
2019 · Pooja Ghatalia, Chad H. Smith, et al. · Frontiers in Oncology · 15
PDF
The Prognostic Significance of CD79B Mutation in Diffuse Large B-Cell Lymphoma: A Meta-analysis and Systematic Literature Review
2022 · Peng-Peng Xu, Rong Shen, et al. · Clinical Lymphoma Myeloma & Leukemia · 11
Outcomes of Follicular Lymphoma Patients Treated with Frontline Bendamustine and Rituximab: Impact of Histologic Grade and Early Progression on Overall Survival
2018 · Allison M. Winter, Loretta J. Nastoupil, et al. · Blood · 10
Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas
2018 · Yang Liu, Jing Ma, et al. · Pathology - Research and Practice · 9
Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy
2018 · Nicole A Carreau, Orrin Pail, et al. · Blood · 8
[Correlation and Influencing Factors of SUVmax and Ki-67 in Non-Hodgkin Lymphoma].
2022 · Juan Li, Ming Zhao, et al. · PubMed · 4
A prognostic 15-gene model based on differentially expressed genes among metabolic subtypes in diffuse large B-cell lymphoma
2023 · Jun Hou, Peng Guo, et al. · Pathology & Oncology Research · 3
PDF
Safety and efficacy of GVD and anti-PD-1 (SHR-1210) regimen with or without low-dose decitabine priming for refractory bulky and aggressive primary mediastinal large B-cell lymphoma.
2018 · Wenying Zhang, Yang Liu, et al. · Journal of Clinical Oncology · 3
End-of-Life Care in Hematology/Oncology Fellowship
2024 · Madeline J. Albert, Yang Liu, et al. · Journal of Palliative Medicine · 1
PDF
Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy
2018 · Nicole A Carreau, Orrin Pail, et al. · Blood · 1
End-of-life (EOL) care in medical oncology fellows' clinics.
2017 · Yang Liu, Chethan Ramamurthy, et al. · Journal of Clinical Oncology · 1
Randomized Clinical Trials in Gastrointestinal Stromal Tumors
2017 · Yang Liu, Margaret von Mehren · Surgical Oncology Clinics of North America · 1
Treatment for orbital diffuse large B-cell lymphoma in an elderly patient by autologous cytokine-induced killer cells
2011 · Su-Xia Li, Hong-Li Zhu, et al. · Annals of Hematology · 1
Profound Decrease of dFLC After One Cycle Predicts Superior Outcome in Patients with AL Amyloidosis Treated with Daratumumab and Bortezomib-Based Regimens
2025 · Yang Liu, Jingyi Bi, et al. · Clinical Lymphoma Myeloma & Leukemia
Supplementary fig 5 from Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy
2023 · Chunmeng Wang, Yang Liu, et al.
Supplementary fig 3 from Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy
2023 · Chunmeng Wang, Yang Liu, et al.
Supplementary fig 2 from Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy
2023 · Chunmeng Wang, Yang Liu, et al.
Supplementary Data from Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy
2023 · Chunmeng Wang, Yang Liu, et al.
Works count: 40
Citation count: 745
H-index: 10
I10-index: 10
Year
Topic
Type